Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Suzhou Shengdiya Biomedical Co., Ltd.'s injectable Rukang Qutub monoclonal antibody has been included in the list of proposed breakthrough therapies by the National Medical Products Administration's Drug Review Center, with the intended indication for use in patients with recurrent or metastatic cervical cancer expressing HER2 (IHC≥1+) who have failed previous treatment with platinum-based chemotherapy and immune checkpoint inhibitors. This product has been included in the proposed breakthrough therapy list for the 8th time.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
Howard Marks' latest discussion talks about the importance of luck and how to make oneself luckier.
Meituan's Q4 revenue reached 88.487 billion yuan, a year-on-year increase of 20.1%, and losses in new Business have significantly narrowed.
Musk: The production of Optimus Siasun Robot&Automation has been realized at the Fremont factory, with a production target of 5,000 units this year.
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
恒瑞医药:子公司注射用瑞康曲妥珠单抗纳入拟突破性治疗品种公示名单
Jiangsu Hengrui Pharmaceuticals: A subsidiary's injectable rituximab has been included in the list of proposed breakthrough therapies.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 269
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report